FINANCIAL ANALYST – BIOTECH The Financial Analyst reports to the COO and works closely with other Senior Management. Key areas of focus are: assisting with the consolidated financials and forecasts/budgets working with corporate accounting personnel to ensure proper expense recognition and compliance with internal controls. all aspects of fundraising for this private company working cross-functionally …
This distinguished awards program celebrates the unstoppable entrepreneurs whose unbounded ambitions deliver innovation, growth and prosperity that transform our world. NORTH BRUNSWICK, N.J., June 4, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announces …
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell inflammatory cytokines. MORRISTOWN, N.J., April 8, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio …
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced today that it has completed enrollment for its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia. This study assesses BioAegis’ …
We are excited to announce that BioAegis Chief Executive Officer, Dr. Susan Levinson, has been appointed to the BioNJ Board of Directors. BioNJ is the life sciences trade association for New Jersey with nearly 400 Member companies representing research-based life sciences organizations and stakeholders across the ecosystem from the largest biopharmaceutical companies to early stage start-ups. BioNJ is …
March 2021: BioAegis CEO, Dr. Susan Levinson, appointed to BioNJ Board Read More »
An immune-based biomarker signature is associated with mortality in COVID-19 patients. (2020, November 24). Https://Insight.Jci.Org/Articles/View/144455. https://insight.jci.org/articles/view/144455 Abstract Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels …
An immune-based biomarker signature is associated with mortality in COVID-19 patients Read More »
Virtual Conference: Navigating Unprecedented Global Uncertainty Tuesday, October 6th and Wednesday, October 7th 2020 Developed with J.P. Morgan and Johnson & Johnson Innovation, BioNJ’s Virtual Two-Day BioPartnering Conference will bring together life sciences professionals from the Northeast and beyond. Last year’s Conference convened attendees representing 17 states and 5 countries. Come ready to meet investors, industry executives and partnering professionals; …
October 6-7, 2020: BioNJ’s 10th Annual BioPartnering Conference Read More »
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announces publication of “Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.” Recombinant human plasma gelsolin …
BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic Morristown, NJ, August 17, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that recent publications of independent studies have reported that low levels of gelsolin are …
Morristown, NJ, August 5, 2020 (GlobeNewswire) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that it enrolled its first patient in its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia. This study assesses BioAegis’ therapeutic, …
LOCATION:
BioAegis Therapeutics
North Brunswick, NJ
MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com
INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com
©2023 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use